<\/p>\n
Trivastal LA<\/strong> is een oraal piribedil<\/strong> (50 mg long-acting) tablet \u2014 a non-ergot dopamine agonist<\/strong> gebruikt voor de behandeling van Parkinson disease<\/strong> (and as adjunctive treatment for chronic vascular cognitive symptoms in some markets). It directly stimulates dopamine D2\/D3 receptors in the brain, partially substituting for the dopamine that is no longer being made. Piribedil is widely used across Europe and Asia but is less prescribed in the US and UK. It has additional α2 noradrenergic antagonism that may improve attention and cognitive symptoms. Critical safety signals:<\/strong> impulscontrole-stoornissen<\/em> (gambling, hypersexuality, binge eating, compulsive shopping), sudden-onset sleep<\/em> (sleep attacks while driving), and orthostatic hypotension. Dose must be titrated up slowly and tapered down slowly — never stopped abruptly.<\/p>\n<\/div>\n \ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n Trivastal LA is an oral tablet containing piribedil 50 mg long-acting<\/strong>. piribedil is a non-ergot dopamine D2\/D3 receptor agonist<\/strong>, originally introduced as Trivastal Retard<\/strong>. Trivastal LA is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n Piribedil is a non-ergot dopamine agonist with mixed pharmacology: it stimulates dopamine D2 and D3 receptors, and additionally antagonises<\/em> presynaptic alpha2-adrenergic receptors. The alpha2 antagonism may produce mild beneficial effects on attention, cognition and mood that are less prominent with other dopamine agonists. It is widely prescribed across Europe and Asia. It is also sometimes used in vascular cognitive symptoms in older patients, although evidence for this is weaker than for Parkinson disease.<\/p>\n Piribedil stimulates dopamine D2 and D3 receptors in the striatum and limbic system, partially substituting for missing dopamine. Distinctively, it also blocks presynaptic alpha2 adrenergic receptors — this de-inhibits noradrenergic neurones and modestly raises noradrenaline release in the prefrontal cortex. The net effect: dopaminergic relief of motor symptoms plus a modest noradrenergic boost on attention and arousal. It does not affect 5-HT2B receptors, so does not cause cardiac valve fibrosis.<\/p>\n Trivastal LA is appropriate for adults with Parkinson disease (as monotherapy in early disease or adjunct to levodopa in advanced disease). It is particularly considered in patients with prominent fatigue, poor attention or apathy, where the alpha2 antagonism may help. It is also used (mostly in Europe and Asia) for chronic peripheral arterial circulation problems and adjunctive vascular cognitive symptoms — though Parkinson disease is the principal indication.<\/p>\n Dopamine agonist therapy must<\/strong> be titrated upwards over weeks to avoid intolerable nausea, postural hypotension and somnolence. The dose schedule below is a typical starting framework — your neurologist will tailor it to your response.<\/p>\nWaarom bestellen bij MedsBase<\/h3>\n
What Is Trivastal LA?<\/h2>\n
How Does Trivastal LA (piribedil) Work?<\/h2>\n
Who Is Trivastal LA For?<\/h2>\n
Dosing and Titration<\/h2>\n